RT Journal Article
T1 Pharmacological interactions of phosphate binders.
T2 Interacciones farmacológicas de los captores del fósforo.
A1 Bover Sanjuan, Jordi
A1 Navarro-Gonzalez, Juan Francisco
A1 Arenas, M Dolores
A1 Torregrosa, Jose-Vicente
A1 Tamargo Menendez, Juan
A1 de Francisco, Angel Luis Martin
A1 Gonzalez-Parra, Emilio
A1 Lloret Cora, M Jesus
A1 Sanchez Alvarez, J Emilio
A1 Martin-Malo, Alejandro
A1 Molina Vila, Pablo
A1 Bajo, M Auxiliadora
A1 DaSilva Santos, Iara
K1 Phosphates
K1 Fibroblast growth factor-23
K1 Aging, premature
K1 Electronic mail
K1 Renal insufficiency, chronic
AB The use of phosphate binders is one of basic elements in the treatment of CKD-MBD (“Chronic Kidney Disease-Mineral and Bone Disorder”). It has been well known for decades that phosphate reten tion through direct and indirect mechanisms, contributes to the generation and progression of secondary hyperparathy roidism (SHP) and renal osteodystrophy in chronic kidney disease (CKD).1,2 In fact, phosphate retention blocks all DOI of original article: https://doi.org/10.1016/j.nefro.2018.05.003. ∗ Corresponding author. E-mail address: jbover@fundacio-puigvert.es (J. Bover Sanjuán). hormonal counter-regulatory mechanisms, increases skeletal resistance to PTH and is considered a central factor in the and systemic alterations such as the decrease in calcitriol, increase in fibroblast growth factor-23 (FGF-23), cardiovascular calcifications, premature aging and the high morbi-mortality of these patients.2,3 For all this, phosphate has been considered as “the silent killer” of patients with CKD 
PB Elsevier
YR 2018
FD 2018-07-07
LK http://hdl.handle.net/10668/13229
UL http://hdl.handle.net/10668/13229
LA en
LA es
NO Bover Sanjuán J, Navarro-González JF, Arenas MD, Torregrosa JV, Tamargo Menéndez J, de Francisco ALM, et al. Pharmacological interactions of phosphate binders. Nefrologia (Engl Ed). 2018 Nov-Dec;38(6):573-578. English, Spanish
DS RISalud
RD Apr 8, 2025